Kite Pharma – $410 Million Shelf‑Takedown Offering

San Francisco – March 22, 2017 – Cooley advised Kite Pharma on its $409.7 million shelf-takedown offering of 5,462,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 712,500 additional shares.

Jefferies acted as the sole book-running manager for the offering. Cowen and Company, RBC Capital Markets and Guggenheim Securities acted as co-managers.

Kite Pharma, which trades on The NASDAQ Global Select Market as “KITE,” is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to target and kill cancer cells.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Charles Bair Partner, San Diego
Charlie Kim Partner, San Diego
Nicole P. van de Leuv Associate, San Diego
Phillip McGill Associate, San Diego
Austin Day Associate, San Diego
Denise Stark Paralegal Specialist, San Diego
Natasha Leskovsek Partner, Washington, DC
Mark Windfeld-Hansen Partner, Palo Alto
Susan Cooper Philpot Partner, San Francisco